ACTIVA CRO is the Argentine regional full-service house that keeps showing up when a U.S. founder types ACTIVA CRO, LATAM CRO Argentina, or Latin America full-service CRO. The firm is real. The website is live. The product is not a boutique first-in-human implant franchise, even though “First in Human” and “Pivotal studies in Medical Devices” sit on the company page.
bioaccess® already publishes a comparison page at bioaccessla.com/compare/activa-cro. Do not treat this article as a second grid of the same claims. This is the public-record piece: what activa-cro.com actually says (retrieved 23 August 2026), what ISO 9001 in 2006 does and does not prove, and when a U.S. device FIH should hire a specialist instead of a southern-cone full-service engine.
No named device sponsors appear on the public site. We will not invent any.
What ACTIVA CRO publishes
The homepage and company page describe ACTIVA CRO as a full-service Contract Research Organization with operations in Latin America, serving CRO, biotech, pharmaceutical, and medical-device clients. Founded in 2003, it “rapidly expanded to Argentina, Chile, Uruguay, Brazil, Peru, Mexico, and Colombia” and calls itself a “southern cone” provider. A 2008 timeline item says the firm was “shaped as a Regional CRO,” then added Panama, Costa Rica, and Ecuador. The FAQ country list is Argentina, Uruguay, Chile, Brazil, Colombia, Mexico, Peru, Ecuador, Costa Rica, and Panama.
The home page publishes a mix graphic: 34% CRO, 32% pharmaceutical, 17% biotech, 17% medical-device industry. Those are company-published percentages, not an audited book of business we have seen. Read them as marketing mix, not as a diligence finding.
The company page says ACTIVA brings experience “in all Clinical trial phases and major therapeutic indications, including Oncology, Hematology, Cardiovascular, Orphan Diseases, CNS, First in Human, and Pivotal studies in Medical Devices,” with senior project managers that “bring an average of 10 years of experience” — their claim. Services listed: medical affairs, regulatory affairs, project monitoring, legal sponsor representation, clinical project oversight, investigator contract negotiation, feasibility, inspection readiness, start-up, clinical staffing, and quality assurance.
Public managers on the company page: Gabriel Desanto, Clinical Operations Director; Mariano Monteagudo, Business Development Director. Founders are described as senior ClinOps / RA professionals; individual founder names are not on the company page fetched for this article.
ISO 9001. The FAQ, live 23 August 2026, states: in 2006, Activa-CRO (South American) was granted ISO 9001:2000 certification on “Control and surveillance on clinical research trial processes for the development of drugs, biological products and medical devices,” recertified ISO 9001:2008, issued by Bureau Veritas and accredited by UKAS, ANAB, and OAA. That is a 2006 quality-system credential that explicitly includes medical devices. It is not a named implant EFS. It is not current-year ISO 9001:2015 evidence unless the firm shows a later certificate. Ask for the current certificate in the RFP.
The homepage has a “customers” block. The fetch did not yield named device-sponsor logos as text. No named device protocol or sponsor is treated as a fact in this article.
Where a regional LATAM full-service CRO is the right tool
Hire ACTIVA when the protocol is a multi-country Latin American program across phases — oncology, hematology, CNS, rare disease, or a later-phase device — and you want one southern-cone vendor that will also be legal sponsor representative, negotiate investigator contracts, and staff monitors. That is a real product. The compare page already says so: if you need Phase I–IV devices and pharma under one regional roof, ACTIVA is in-category.
Do not assume “First in Human” plus “Pivotal studies in Medical Devices” on a capabilities paragraph equals a U.S. startup’s first five-to-thirty implants designed from a Pre-Sub. Full-service regional CROs list FIH because they will take the work. Specialist FIH CROs list FIH because that is the only work. The diligence question is the TMF, not the bullet.
The product a U.S. device FIH actually buys
A U.S. medtech FIH/EFS implant study is a different product from a LATAM full-service Phase II–III:
- The article is a device, often an implant or delivery system, under ISO 14155, not only ICH E6.
- The customer for the package is FDA (Pre-Sub, IDE, 21 CFR 812.28), not only ANMAT or INVIMA.
- Import, sterilization, device accountability, and procedure-room source data dominate start-up.
- n is small. Staffing must not look like a regional pharma engine.
- The operating language and headquarters the CEO will call are usually English and U.S. Eastern Time.
bioaccess® is built as that product. Co-founded 2010 by Dr. Pedro Martinez-Clark, Dr. William O’Neill, and Julio G. Martinez-Clark. IMH ASSETS CORP. Miami headquarters. Regional offices in Bogotá, Mexico City, Santiago, São Paulo, and Buenos Aires — Argentina is already an execution geography. FIH-only since 2010. 50+ pre-qualified sites, 19 countries; 50+ FIH/EFS supported; 50+ clients (about page).
In Colombia, bioaccess® still runs trials (23 August 2026), keeps a local entity and office, manages INVIMA clocks in-country, and has 30+ historical FIH device studies and 20+ sites in Bogotá, Cali, Medellín, and Barranquilla. We do not recommend taking new first-in-human work out of Colombia. See CRO in Colombia. Commercial registro sanitario is a separate live service, including ANMAT.
ACTIVA CRO vs bioaccess® — device FIH comparison
| Dimension | ACTIVA CRO | bioaccess® |
|---|---|---|
| Home country | Argentina-origin regional CRO (2003) | United States HQ (Miami); local LATAM entities including Colombia and Argentina office |
| Published mix | Company graphic: 34% CRO / 32% pharma / 17% biotech / 17% device | FIH/EFS is the core offer |
| FIH / device language | First in Human and pivotal medical-device studies claimed on the company page | Device FIH/EFS specialist since 2010 |
| Named device EFS / sponsors | None on public site | Published case studies on bioaccessla.com |
| Quality claim | ISO 9001:2000 granted 2006 for control/surveillance of drug, biologic, and device trials; recertified 9001:2008 (FAQ) | ISO 14155 device investigations; 812.28-ready English data room |
| Leadership (site) | Gabriel Desanto (ClinOps); Mariano Monteagudo (BD) | Julio G. Martinez-Clark, CEO; Pedro Martinez-Clark, CMO; William O’Neill |
| Footprint | AR, UY, CL, BR, CO, MX, PE, EC, CR, PA (FAQ) | 19 countries; 50+ pre-qualified sites |
| After the trial | Full-service clinical + RA / legal sponsor representation | Live multi-country sanitary registration / in-country holder |
How to keep ACTIVA on the list without confusing the job
If the protocol is a regional LATAM pivotal or a multi-country pharma/device program and Argentina is the operating center of gravity, ACTIVA is in-category. If the protocol is a first implant for a U.S. device company, put ACTIVA in the “regional full-service / possible later-phase or local partner” column and put bioaccess® in the “prime FIH CRO” column. Then ask ACTIVA for a named or de-identified device EFS: class, implant versus non-implant, n, ISO 14155 monitoring plan, English TMF, and FDA-file use. If that package exists, the two firms can split work — FIH with the specialist, later phase with the regional house. The compare page already contemplates that handoff.
Argentine and regional peers already covered: LAT Research, RARAS, Cohortias. Panama specialist: First in Humans. Request a proposal at contact.
FAQ — ACTIVA CRO and device FIH
Is ACTIVA CRO a first-in-human CRO?
It lists First in Human among phases and indications, next to oncology, hematology, CNS, and pivotal medical-device studies. That is a full-service menu. It is not a published implant case series.
Does ACTIVA have ISO 9001?
The live FAQ says ISO 9001:2000 was granted in 2006 for control and surveillance of drug, biologic, and medical-device trial processes, recertified ISO 9001:2008. Ask for the current certificate. Do not treat a 2006 grant as a 2026 named EFS.
Who leads ACTIVA?
The company page names Gabriel Desanto (Clinical Operations Director) and Mariano Monteagudo (Business Development Director).
Is bioaccess® a direct competitor?
Only in a narrow slice — the first-in-human device (and FIH biopharma/radiopharma) job. For Phase II–IV regional coverage, ACTIVA is often the better fit. See the compare page.
Does bioaccess® still run studies in Colombia?
Yes. Local Colombian entity and office, INVIMA clocks in-country, commercial registro sanitario as a separate live service.
Competitor facts from activa-cro.com, /company/, and /faq/, 23 August 2026. bioaccess® facts from bioaccessla.com. No invented emails, sponsor names, or day-count medians. ACTIVA mix percentages and “average of 10 years” are their company claims.